hero image

Biogen Idec Stockholders Elect Company's Board Nominees

June 19, 2008 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB) today announced that, based on a preliminary count provided by its proxy solicitor, stockholders have elected all four of the Company’s nominees – Cecil B. Pickett, Ph.D., Lynn Schenk, J.D., Phillip A. Sharp, Ph.D., and Stelios Papadopoulos, Ph.D. – to the Biogen Idec Board of Directors at today’s Annual Meeting of Stockholders. In addition, based on that preliminary count, the proposal to amend the Company’s bylaws to set the size of the Board at 12 has been defeated. The preliminary count is subject to the official tabulation of vote results, which will be provided by Biogen Idec’s independent inspector of elections, IVS Associates, Inc., in approximately 2-3 weeks.

Bruce R. Ross, Biogen Idec’s Chairman, said, “We are gratified that our nominees will serve on the Biogen Idec Board of Directors. Our Board has a track record of delivering stockholder value and is committed to pursuing all avenues to continue to do so in the future. We look forward to turning our undivided attention to delivering strong performance and growing our business for stockholders.”

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

Contact:

Biogen Idec Media Contact:
Naomi Aoki, 617-914-6524
Director, Public Affairs
or
Biogen Idec Investor Relations Contact:
Elizabeth Woo, 617-679-2812
Vice President, Investor Relations

thumb
March 22, 2023
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System

thumb
March 17, 2023
Biogen to Participate in the Stifel 2023 CNS Days

Cambridge, MA, - -  Biogen Inc.   (Nasdaq: BIIB) announced today that Priya Singhal, M.D., M.P.H., Head of Development, will participate in the Stifel 2023 CNS Days. The webcast will be live on Tuesday, March 28, 2023, at 9:15 a.m. ET. To access the live webcast, please visit the Investors section